Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.75 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.75 |
| ▸ | RAB9A | P51151 | 2/20 | 0.75 |
| ▸ | NPC1 | O15118 | 1/20 | 0.75 |
| ▸ | PKM | P14618 | 1/20 | 0.75 |
| ▸ | CRHBP | P24387 | 1/20 | 0.75 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.75 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.71 |
| ▸ | LMNA | P02545 | 1/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.63 |
| ▸ | POLB | P06746 | 2/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.60 |
| ▸ | HCAR3 | P49019 | 5/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22382354 | 0.83 | MAPT (0.81) | MAPTALDH1A1RAB9ANPC1PKM | |
| SCHEMBL9043097 | 0.83 | MAPT (0.84) | MAPTALDH1A1RAB9ANPC1PKM | |
| SCHEMBL1964842 | 0.83 | MAPT (1.00) | MAPTALDH1A1RAB9ANPC1PKM | |
| SCHEMBL22382490 | 0.82 | MAPT (0.78) | MAPTALDH1A1RAB9ANPC1PKM | |
| SCHEMBL15321333 | 0.82 | MAPT (0.82) | MAPTALDH1A1RAB9ANPC1PKM | |
| SCHEMBL15774665 | 0.81 | MAPT (0.87) | MAPTALDH1A1RAB9ANPC1PKM | |
| SCHEMBL22382547 | 0.81 | MAPT (0.77) | MAPTALDH1A1RAB9ANPC1PKM | |
| SCHEMBL7972061 | 0.80 | MAPT (0.75) | MAPTALDH1A1RAB9ANPC1PKM | |
| SCHEMBL1965205 | 0.80 | KMT2A (0.76) | MAPTALDH1A1RAB9ANPC1PKM | |
| SCHEMBL15774548 | 0.78 | ALDH1A1 (0.72) | MAPTALDH1A1RAB9ANPC1PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080103138-A1 | Beta-agonists, methods for the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-05-01 | — | — | US | disclosed |
| US-20080103138-A1 | Beta-agonists, methods for the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-05-01 | — | — | US | disclosed |
| US-20070112033-A1 | N-(3-{2-[3-(6-amino-benzimidazol-1-yl)-1,1-dimethyl-propylamino]-1-hydroxy-ethyl}-phenyl)-benzenesulphonamide; beta(3)-Adrenoceptor agonists; antidiabetic, obesity, insulin resistance | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-05-17 | — | — | US | disclosed |
| US-20070112033-A1 | N-(3-{2-[3-(6-amino-benzimidazol-1-yl)-1,1-dimethyl-propylamino]-1-hydroxy-ethyl}-phenyl)-benzenesulphonamide; beta(3)-Adrenoceptor agonists; antidiabetic, obesity, insulin resistance | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080103138-A1 | Beta-agonists, methods for the preparation thereof and their use as pharmaceutical compositions | ADRB1, ADRB3, ADRB2 | MAPT 468/4885ALDH1A1 717/4885RAB9A 1706/4885 |
| US-20070112033-A1 | N-(3-{2-[3-(6-amino-benzimidazol-1-yl)-1,1-dimethyl-propylamino]-1-hydroxy-ethyl}-phenyl)-benzenesulphonamide; beta(3)-Adrenoceptor agonists; antidiabetic, obesity, insulin resistance | ADRB3, ADRB1, ADRA1B | MAPT 1004/4885ALDH1A1 573/4885RAB9A 1943/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.